Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

President Donald Trump's new health care initiative aims to reduce prescription drug costs by targeting pharmacy benefit managers, commonly known as PBMs.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...